Rabbit-Milk clotting drug tested for hemophilia bleeds
NCT ID NCT04647227
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing the safety of a drug called SEVENFACT, a clotting factor made from the milk of genetically modified rabbits, in people aged 12 and older with hemophilia A or B who have inhibitors. The drug is already approved for treating bleeding episodes, and this trial will monitor side effects in 55 participants across the US. It is an open-label study, meaning everyone knows they are getting the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SEVENFACT (a clotting factor made from rabbit milk)
- What this could lead to
- If successful, this could confirm that SEVENFACT is a safe option to control bleeding episodes in people with hemophilia who have inhibitors.
- What could go wrong
- This is a small, early-phase safety study (55 people) with no comparison group, so it cannot prove effectiveness. Side effects like allergic reactions or blood clots are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A WITH INHIBITOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arizona Hemophilia and Thrombosis Center at Phoenix Children's Hospital
COMPLETEDPhoenix, Arizona, 85016, United States
-
Arkansas Center for Bleeding Disorders
RECRUITINGLittle Rock, Arkansas, 72202, United States
-
Arnold Palmer Hospital for Children - The Haley Center for Children's Cancer and Blood Disorders
COMPLETEDOrlando, Florida, 32806, United States
-
Brody School of Medicine at East Carolina University
NOT_YET_RECRUITINGGreenville, North Carolina, 27834, United States
-
Center for Bleeding and Clotting Disorders, University of Minnesota
NOT_YET_RECRUITINGMinneapolis, Minnesota, 55455, United States
-
Children's Hospital of Michigan
RECRUITINGDetroit, Michigan, 48201, United States
-
Children's National Hemophilia Center
COMPLETEDWashington D.C., District of Columbia, 20010, United States
-
Gulf States Hemophilia and Thrombophilia Center-University of Texas Health Science Center @Houston
RECRUITINGHouston, Texas, 77030, United States
-
Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory, Adult Division
RECRUITINGAtlanta, Georgia, 31404, United States
-
Henry Ford Health System
RECRUITINGDetroit, Michigan, 48202, United States
-
Kansas City Regional Hemophilia Center
RECRUITINGKansas City, Missouri, 64108, United States
-
MSU Center for Bleeding and Clotting Disorders
RECRUITINGLansing, Michigan, 48912, United States
-
Massachusetts General Hospital Comprehensive Hemophilia and Thrombosis Treatment Center
RECRUITINGBoston, Massachusetts, 02114, United States
-
Mayo Comprehensive Hemophilia Center
COMPLETEDRochester, Minnesota, 55905, United States
-
Northwell Health, Long Island Jewish
RECRUITINGNew Hyde Park, New York, 11040, United States
-
Oklahoma Center for Bleeding and Clotting Disorders
RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
Orthopaedic Institute for Children
RECRUITINGLos Angeles, California, 90007, United States
-
University Hospitals Health System Cleveland
RECRUITINGCleveland, Ohio, 44106, United States
-
University of California at Davis UC Davis Hemostasis and Thrombosis Center
RECRUITINGSacramento, California, 95817, United States
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37212, United States
-
Willett Children's Hospital at Memorial University Medical Center
RECRUITINGSavannah, Georgia, 31404, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.